Drug Trial Radar · NCT00407745
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Jan 2007
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 5, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.
Conditions
- Neuralgia
- Spinal Cord Injuries
Interventions
placeboDrug
Placebo
pregabalinDrug
Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration Adjusted Average Change (DAAC) of Mean Pain ScoreTime frame: Baseline, Week 16
Locations
67 sites in 10 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
Napa, California
Pfizer Investigational Site
Northridge, California
Pfizer Investigational Site
Pasadena, California
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Overland Park, Kansas
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
White Plains, New York
Pfizer Investigational Site
Winston-Salem, North Carolina
Pfizer Investigational Site
Bellevue, Ohio
Pfizer Investigational Site
Johnstown, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania
Pfizer Investigational Site
Dallas, Texas
Pfizer Investigational Site
Charleston, West Virginia
Pfizer Investigational Site
Charleston, West Virginia
Pfizer Investigational Site
Viña del Mar, Valparaiso, Chile
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, Beijing Municipality, China
Pfizer Investigational Site
Chengdu, Sichuan, China
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Brno, Czechia
Pfizer Investigational Site
Liberec, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Hong Kong, Hong Kong
Pfizer Investigational Site
New Delhi, India
Pfizer Investigational Site
Secunderabad, Andhra Pradesh, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Mangalore, Karnataka, India
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Tokushima, Japan
Pfizer Investigational Site
Yamagata, Japan
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.